Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI) will present 19 studies at the San Antonio Breast Cancer Symposium (SABCS) from Dec 9–12, 2025. The research spans seven breast cancer subtypes (HR+/HER2–, HER2+, HER2-low/ultralow/null, triple-negative, invasive lobular, male, metastatic) and reflects multi-omics tumor profiling, whole exome/transcriptome sequencing, IHC, and AI-driven signatures.

Two studies are selected for oral/rapid oral presentation focusing on multimodal AI for recurrence prediction and late distant recurrence risk. The 19 studies involve 40+ collaborating institutions and Caris Precision Oncology Alliance (Caris POA), which includes 98 centers with 45 NCI-designated cancer centers. Abstracts and poster summaries will be available onsite at Caris booth #209 and later on the company website.

News Market Reaction – CAI

+3.05%

1 alert

+3.05% News Effect

On the day this news was published, CAI gained 3.05%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Studies at SABCS: 19 studies Breast cancer subtypes: 7 subtypes Oral presentations: 2 studies +5 more

8 metrics

Studies at SABCS 19 studies San Antonio Breast Cancer Symposium, Dec 9–12, 2025

Breast cancer subtypes 7 subtypes HR+/HER2–, HER2+, HER2-low/ultralow/null, TNBC, ILC, male, metastatic

Oral presentations 2 studies Oral and rapid oral presentations on AI recurrence models

Caris POA members 98 centers Members of Caris Precision Oncology Alliance

NCI-designated centers 45 centers Within Caris Precision Oncology Alliance

Caris booth #209 SABCS 2025 exhibit location for poster and abstract summaries

Conference dates Dec 9–12, 2025 San Antonio Breast Cancer Symposium

Oral session time 11:30–11:45 AM CST General Session 1 oral presentation on Dec 10, 2025

Market Reality Check

Price: $18.20 Vol: Volume 2,016,497 is below...

normal vol

$18.20 Last Close

Volume Volume 2,016,497 is below 20-day average of 2,451,531 (relative 0.82x). normal

Technical Price 26.54 trades below 200-day MA of 40.17 and 52.79% below 52-week high.

Peers on Argus

CAI slipped 0.18% while key biotech peers were mixed: MDGL, MRNA and ROIV rose (...

CAI slipped 0.18% while key biotech peers were mixed: MDGL, MRNA and ROIV rose (2.18%, 2.42%, 5.38%), HALO fell 1.43%, and VRNA was nearly flat. This points to company-specific trading rather than a unified sector move around the SABCS-related news.

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Scientific conference update	Positive	+3.0%	Announcement of 19 SABCS studies across multiple breast cancer subtypes.
Dec 02	Alliance expansion	Positive	+0.2%	Addition of UAMS cancer institute to Precision Oncology Alliance.
Nov 21	Education program	Positive	+0.3%	Launch of 2025/2026 POA Fellows Forum class using CODEai database.
Nov 17	Investor conferences	Neutral	-0.6%	Participation in multiple Q4 2025 healthcare investor conferences.
Nov 05	Earnings and guidance	Positive	-6.3%	Q3 2025 beat with higher revenue guidance but negative price reaction.

Pattern Detected

Non-earnings news has generally seen small positive alignment, while strong earnings and guidance in Q3 2025 coincided with a negative price reaction, hinting at a pattern of selling into financial strength.

Recent Company History

Over the past months, Caris reported strong growth, with Q3 2025 revenue of $216.8M, net income of $24.3M, and higher 2025 revenue guidance, yet the stock fell 6.32% after those earnings. Subsequent news has focused on alliance expansion, education initiatives, and investor conference participation, each with modest moves. The current SABCS announcement, highlighting 19 breast cancer studies and multi-omics/AI capabilities across seven subtypes and the 98-member Caris POA, continues this theme of scientific and network building.

Market Pulse Summary

This announcement highlights Caris’ research depth, with 19 breast cancer studies at SABCS spanning ...

Analysis

This announcement highlights Caris’ research depth, with 19 breast cancer studies at SABCS spanning seven subtypes and featuring multimodal AI models for recurrence and risk prediction. It reinforces the scale of the Caris Precision Oncology Alliance with 98 centers, including 45 NCI-designated cancer centers. In context of earlier strong Q3 2025 financials and ongoing alliance growth, investors may watch how these scientific outputs translate into clinical adoption and revenue over time.

Key Terms

multi-omics, ihc, triple-negative breast cancer, antibody drug conjugates, +2 more

6 terms

multi-omics medical

"multi-omics-driven profiling, subtyping and biomarker discovery accelerate precision oncology"

Multi-omics is a comprehensive approach that combines different types of biological data—such as genetic information, proteins, and other molecules—to gain a detailed understanding of how living systems function. For investors, this approach can reveal insights into health, disease, or biological processes that may influence the development of new treatments or technologies, potentially impacting market opportunities and innovation in healthcare.

ihc medical

"integrating whole exome and whole transcriptome sequencing with IHC profiling"

Immunohistochemistry (IHC) is a laboratory technique that uses labeled antibodies to detect and visually highlight specific proteins inside tissue samples, producing stained patterns pathologists can see under a microscope. For investors, IHC matters because it helps confirm whether a drug or diagnostic hits the intended target in real patient tissues and can support patient selection, clinical trial design and regulatory filings — essentially acting like a map that shows where a therapy is likely to work and reducing clinical and regulatory risk.

triple-negative breast cancer medical

"Chemokine signatures improve PD-L1-based prediction of pembrolizumab response in triple-negative breast cancer"

Triple-negative breast cancer is a type of breast cancer that lacks three common markers used to identify and treat the disease effectively. Because it doesn’t respond to some targeted therapies, it can be more difficult to treat and may have a more aggressive progression. This impacts the development of new treatments and can influence the outlook for healthcare companies involved in cancer research and pharmaceuticals.

antibody drug conjugates medical

"Comparative efficacy of antibody drug conjugates (ADCs) in male versus female breast cancer"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

ngs medical

"PTEN loss by IHC and PTEN alteration by NGS in Metastatic HR-Positive"

A laboratory method that reads large amounts of DNA or RNA quickly to identify genetic differences, mutations, or microbes, similar to scanning many pages of a book at once to find important words. Investors care because it drives diagnostics, drug discovery and personalized treatments, can create recurring revenue from testing services and instruments, and influences regulatory approvals, partnerships and market value in biotech and healthcare companies.

pd-l1 medical

"Chemokine signatures improve PD-L1-based prediction of pembrolizumab response"

PD-L1 is a protein found on the surface of some cells that acts like a stop sign for the immune system, telling certain immune cells to back off. It matters to investors because many cancer drugs and diagnostic tests target or measure PD-L1 to unlock immune responses or predict which patients will benefit, affecting clinical success, regulatory approval, and potential sales in the oncology market.

AI-generated analysis. Not financial advice.

IRVING, Texas, Dec. 4, 2025 /PRNewswire/ -- Caris Life Sciences^® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, including those within the Caris Precision Oncology Alliance ™ (Caris POA), will collectively present 19 studies across a range of breast cancer types at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025.

The studies investigated seven distinct breast cancer subtypes, including HR+/HER2–, HER2-positive, HER2-low/ultralow/null, triple-negative, invasive lobular carcinoma, male and metastatic. The range of studies demonstrates how multi-omics-driven profiling, subtyping and biomarker discovery accelerate precision oncology and improve patient outcomes. The studies represent 40+ collaborating institutions, including leading NCI-designated cancer centers.

"SABCS is the premier global stage for advancing breast cancer research, and we are excited to share how Caris' multi-omic tumor profiling is helping define molecularly distinct patient groups," said George W. Sledge, Jr., MD, Caris EVP and Chief Medical Officer. "By integrating whole exome and whole transcriptome sequencing with IHC profiling and AI-driven signatures, we are uncovering new insights into therapeutic resistance and real-world outcomes that bring us closer to truly personalized cancer care."

"The selection of two studies we collaborated on for oral and rapid oral presentations underscores Caris' leadership in multimodal AI for recurrence prediction and risk stratification in early and late breast cancer," said Caris President David Spetzler, MS, PhD, MBA.

Oral Presentation:

• Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx. Oral #GS1-09
  • General Session 1. December 10, 2025. 11:30 AM-11:45 AM CST

Rapid Oral Presentation:

• A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer. Rapid Oral #RF3-07
  • Rapid Fire 3. December 10, 2025. 5:18-5:26 PM CST

Spotlight Posters Include:

• Personalized Acquired CDK4/6i Resistance: Associations with Baseline Characteristics Like Obesity in Real-World (RW) Clinical-Multiomics Data. #PD3-02
  • Poster Spotlight 3. December 10, 2025. 7:33-7:36 AM CST
• Overcoming ADC Resistance: Payload Diversification as a Strategy for Sequential Therapy.
  #PD3-11
  • Poster Spotlight 3. December 10, 2025. 8:12-8:15 AM CST
• The Genomic, Transcriptomic, and Immune characterization of Metastatic Lobular Breast Cancer. #PD9-07
  • Poster Spotlight 9. December 11, 2025. 8:00-8:03 AM CST
• Differential Benefit to Elacestrant in a Large Cohort of ER+ Breast Cancer: Impact of ESR1 mutants and prior therapy. #PD10-11
  • Poster Spotlight 10. December 12, 2025. 8:12-8:15 AM CST

Posters Include:

• Outcomes in patients with PIK3CA-mutated breast cancer treated with metformin. #PS1-11-11
  • Poster Session 1. December 10, 2025. 12:30-2:00 PM CST
• Evaluation of steroid hormone receptor expression and clinical outcomes in ER-positive breast cancer bone metastases. #PS1-11-27
  • Poster Session 1. December 10, 2025. 12:30-2:00 PM CST
• Comprehensive Characterization of PTEN loss by IHC and PTEN alteration by NGS in Metastatic HR-Positive, HER2-Negative Breast Cancer-- An Exploratory Analysis of Biomarker Concordance and Co-Occurrence. #PS2-08-02
  • Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
• Site specific Genomic and Immune Landscapes Underpinning in metastatic Male Breast Cancer. #PS2-08-04
  • Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
• Chemokine signatures improve PD-L1-based prediction of pembrolizumab response in triple-negative breast cancer. #PS2-08-14
  • Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
• Tertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) breast cancer (BC) in the Real-World Database. #PS2-09-08
  • Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
• TONSL, an immortalizing oncogene on Chr.8q24.3 amplicon, confers intrinsic resistance to CDK4/6 inhibitors in breast cancer. #PS2-09-19
  • Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
• Combined T and B Cell Signatures as Prognostic Biomarkers in Triple-Negative Breast Cancer (TNBC). #PS2-10-25
  • Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
• Metabolic and Immune Reprogramming via SCD1 Inhibition Enhances Chemo-Immunotherapy Response in TNBC. #PS2-12-07
  • Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
• Immune microenvironment and survival differences among Hispanic and African American breast cancer cases by biopsy site. #PS3-12-06
  • Poster Session 3. December 11, 2025. 12:30-2:00 PM CST
• Comparative efficacy of antibody drug conjugates (ADCs) in male versus female breast cancer across the spectrum of HER2 expression. #PS4-01-13
  • Poster Session 4. December 11, 2025. 5:00 – 6:30 PM CST
• Evaluation of Metabolic Dysregulation, Endocrine Therapy Outcomes, and Tumor Biology in HER2-/HR+ Breast Cancer using a Multi-Omic, Real-World Analysis. #PS4-01-14
  • Poster Session 4. December 11, 2025. 5:00 – 6:30 PM CST
• EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition. #PS4-05-05
  • Poster Session 4. December 11, 2025. 5:00 – 6:30 PM CST

Poster and abstract summaries highlighting this research will be available onsite at Caris' booth #209. The full abstracts will be available on the Caris website following the presentations.

The Caris Precision Oncology Alliance consists of 98 cancer centers, academic institutions, research consortia and healthcare systems, including 45 NCI-designated cancer centers, all collaborating to advance precision oncology and biomarker-driven research. Caris and Caris POA members collaborate to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers, aiming to improve clinical outcomes for cancer patients.

About Caris Life Sciences
Caris Life Sciences^® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. 

Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. 

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions. 

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Quarterly Report on Form 10-Q filed on or about November 5, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. 

Caris Life Sciences Media:  
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-showcase-19-studies-at-the-2025-san-antonio-breast-cancer-symposium-302632548.html

SOURCE Caris Life Sciences

FAQ

How many studies will Caris Life Sciences (CAI) present at SABCS 2025 and when?

Caris will present 19 studies at SABCS from Dec 9–12, 2025.

Which breast cancer subtypes are covered by Caris' SABCS 2025 presentations (CAI)?

The presentations cover seven subtypes: HR+/HER2–, HER2+, HER2-low/ultralow/null, triple-negative, invasive lobular, male, and metastatic disease.

Does Caris (CAI) have oral presentations at SABCS 2025 and what are their topics?

Yes; two selections include oral presentations on multimodal AI models for predicting early and late breast cancer recurrence and late distant recurrence risk in HR+ early breast cancer.

Where can investors find Caris' SABCS 2025 abstracts and posters for CAI?

Poster and abstract summaries will be available at Caris booth #209 onsite, and full abstracts will be posted on Caris' website after the presentations.

How large is the Caris Precision Oncology Alliance (Caris POA) cited in the CAI announcement?

Caris POA comprises 98 centers, including 45 NCI-designated cancer centers collaborating on molecular testing standards and biomarker research.